Original Article

Pediatric Osteosarcoma: A Single Institution's Experience

Authors: Vani Vijayakumar, MD, Rachel Lowery, RN, Xu Zhang, PhD, Chindo Hicks, PhD, Luminita Rezeanu, MD, Jennifer Barr, MD, Henry Giles, MD, Srinivasan Vijayakumar, MD, Gail Megason, MD

Abstract

Objectives: The aim of the study was to evaluate outcomes with an examination of individual predictors influencing survival at a single institution.

Methods: This was a retrospective review of the 28 pediatric osteosarcoma patients diagnosed and studied from 2000 through 2012. Twenty-eight patient charts and imaging studies were reviewed for age, race, sex, location, extent of disease at presentation, imaging results, histology, treatment options, and overall survival.

Results: Of the 28 patients who were identified, the median age at diagnosis was 14 years. The majority of the patients were male African Americans with the tumor located in the lower long bones and most had conventional osteosarcoma histology. Four patients had metastasis at diagnosis. Of the 28 patients, 16 patients underwent limb salvage surgery, 6 underwent amputation, 4 had biopsy only, 1 had hip disarticulation, and 1 moved out of state and had no information available. All 28 patients received chemotherapy. Four patients received additional radiation therapy. On follow-up, 15 patients were still alive at last clinical contact and 13 died. Of the deceased, the median survival time was 2.3 years. The patient who lived the longest survived 8.3 years. Metastasis at diagnosis was associated with poorer outcome ( P = 0.002). The 5-year overall survival rate was 40% (95% confidence interval 18–62) for our entire population of patients.

Conclusions: Survival in our patient cohort tended to be at the lower end of the spectrum reported by other contemporary treatment centers of excellence or Surveillance, Epidemiology, and End Results databases probably because of the large number of African American patients with associated poor socioeconomic status. Future studies should be conducted to explore biological and nonbiological factors that may affect the prognosis in this disease.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Gorlick R, Janeway K, Lessnick S, et al. Children’s Oncology Group’s 2013 blueprint for research: bone tumors. Pediatr Blood Cancer 2013;60:1009-1015.
 
2. Janeway KA, Barkauskas DA, Krailo MD, et al. Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children’s Oncology Group. Cancer 2012;118:4597-4605.
 
3. Daw NC, Neel MD, Rao BN, et al. Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children’s Research Hospital OS99 trial. Cancer 2011;117:2770-2778.
 
4. Harting MT, Lally KP, Andrassy RJ, et al. Age as a prognostic factor for patients with osteosarcoma: an analysis of 438 patients. J Cancer Res Clin Oncol 2010;136:561-570.
 
5. Chou AJ, Kleinerman ES, Krailo MD, et al. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children’s Oncology Group. Cancer 2009;115:5339-5348.
 
6. Bacci G, Longhi A, Versari M, et al. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 2006;106:1154-1161.
 
7. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002;20:776-790.
 
8. Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res 2009;152:3-13.
 
9. Bishaw A. Poverty: 2010 and 2011, American community survey briefs. http://www.census.gov/prod/2012pubs/acsbr11-01.pdf. Published September 2012. Accessed January 29, 2013.
 
10. Cossman JS. Mississippi’s physician labor force: current status and future challenges. J Miss State Med Assoc 2004;45:8-31.
 
11. Pakos EE, Nearchou AD, Grimer RJ, et al. Prognostic factors and outcomes for osteosarcoma: an international collaboration. Eur J Cancer 2009;45:2367-2375.
 
12. Broadhead ML, Clark JC, Myers DE, et al. The molecular pathogenesis of osteosarcoma: a review. Sarcoma 2011;2011:959248.
 
13. Karlson CW, Smith ML, Leist-Haynes S, et al. Risk for psychosocial problems in pediatric cancer: impact of socioeconomics. Children’s Health Care 2013;42:231-247.
 
14. Surveillance, Epidemiology, and End Results Program. SEER data, 1973-2011. http://seer.cancer.gov/data. Accessed September 18, 2014.
 
15. Ries LAG, Smith MA, Gurney JG, et al, eds. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995. NIH Pub. No. 99-4649. Bethesda, MD: National Cancer Institute, SEER Program; 1999.
 
16. Altaf S, Enders F, Jeavons E, et al. High-BMI at diagnosis is associated with inferior survival in patients with osteosarcoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer 2013;60:2042-2046.
 
17. Child and Adolescent Health Measurement Initiative. 2011/12 National Survey of Children’s Health. Enhanced Data File. Data Resource Center for Child & Adolescent Health. http://myemail.constantcontact.com/Dataset-and-Codebook-Now-Available—2011-12-National-Survey-of-Children-s-Health.html?soid=1101849134265&aid=sI8wP-FZ26c. Accessed January 29, 2013.
 
18. Viana MB, Fernandes RA, de Carvalho RI, et al. Low socioeconomic status is a strong independent predictor of relapse in childhood acute lymphoblastic leukemia. Int J Cancer Suppl 1998;11:56-61.
 
19. Nathan SS, Healey JH. Making a case for the socioeconomic determinacy of survival in osteosarcoma. Clin Orthop Relat Res 2013;471:784-791.
 
20. Nathan SS, Healey JH. Demographic determinants of survival in osteosarcoma. Ann Acad Med Singapore 2012;41:390-399.
 
21. Lightfoot TJ, Johnston WT, Simpson J, et al. Survival from childhood acute lymphoblastic leukemia: the impact of social inequality in the United Kingdom. Eur J Cancer 2012;48:263-269.
 
22. DeSantis C, Naishadham D, Jemal A. Cancer statistics for African Americans, 2013. CA Cancer J Clin 2013;63:151-166.
 
23. Worch J, Matthay KK, Neuhaus J, et al. Ethnic and racial differences in patients with Ewing sarcoma. Cancer 2010;116:983-988.
 
24. Homa DM, Sowers MR, Schwartz AG. Incidence and survival rates of children and young adults with osteogenic sarcoma. Cancer 1991;67:2219-2223.
 
25. Gamazon ER, Pinto N, Konkashbaev A, et al. Trans-population analysis of genetic mechanisms of ethnic disparities in neuroblastoma survival. J Natl Cancer Inst 2013;105:302-309.
 
26. Pui CH, Pei D, Pappo AS, et al. Treatment outcomes in black and white children with cancer: results from the SEER database and St Jude Children’s Research Hospital, 1992 through 2007. J Clin Oncol 2012;30:2005-2012.